Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{171019,
        author = {Fahmia Feroz and Dr. Shakir Rasool},
        title = {Rare incidence of  T cell lymphomas after chimeric antigen receptor (CAR)-T cell therapy},
        journal = {International Journal of Innovative Research in Technology},
        year = {2024},
        volume = {11},
        number = {7},
        pages = {1977-1983},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=171019},
        abstract = {Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of various hematologic malignancies, particularly B-cell lymphomas and leukemias[1]. By genetically modifying a patient's T cells to express receptors targeting specific cancer antigens, CAR-T therapy enhances the immune system's ability to recognize and eliminate cancer cells. While CAR-T therapy has demonstrated significant efficacy, its application in T-cell malignancies presents unique challenges[2]. T-cell lymphomas, such as peripheral T-cell lymphoma and cutaneous T-cell lymphoma, are less common and more difficult to treat. The primary obstacle is the phenomenon of "fratricide," where engineered CAR-T cells inadvertently target and destroy other T cells, including both malignant and normal ones[3]. This unintended destruction can hinder the expansion and persistence of CAR-T cells within the patient, potentially compromising the therapy's effectiveness.},
        keywords = {Chimeric Antigen Receptor, hematologic malignancies, B-cell lymphomas, T-cell malignancies, fratricide.},
        month = {December},
        }